Literature DB >> 15337510

Mass spectral fragmentation reactions of angiotensin-converting enzyme (ACE) inhibitors.

David J Burinsky1, Scott L Sides.   

Abstract

A variety of mass spectrometric techniques have been employed in the study of a series of structurally similar compounds used in the treatment of hypertension. The compounds, known collectively as angiotensin-converting enzyme (ACE) inhibitors, all share the amino acid residue proline or some variant thereof, as a common structural element. The gas phase fragmentation behavior of these compounds has been explored systematically using various instruments and techniques. An interesting dissociation process (rearrangement) unique to one of the compounds, lisinopril, has been investigated using isotopic labeling experiments and exact mass measurements. The general nature of the process has been probed through both the positive and negative ion analyses of fourteen related compounds exhibiting structural homology.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15337510     DOI: 10.1016/j.jasms.2004.05.010

Source DB:  PubMed          Journal:  J Am Soc Mass Spectrom        ISSN: 1044-0305            Impact factor:   3.109


  19 in total

1.  Copper and iron interactions with angiotensin-converting enzyme inhibitors. A study by fast-atom bombardment tandem mass spectrometry.

Authors: 
Journal:  Rapid Commun Mass Spectrom       Date:  1999-06       Impact factor: 2.419

2.  The use of deuterium oxide as a mobile phase for structural elucidation by HPLC/UV/ESI/MS

Authors: 
Journal:  Anal Chem       Date:  2000-10-15       Impact factor: 6.986

3.  An unusual rearrangement of Zofenopril, a new ACE inhibitor drug: mass spectrometric and conformational studies.

Authors:  Antonella Cartoni; Maria Altamura; Fabio Animati; Giuseppe Balacco; Riccardo Cosi; Alessandro Ettorre; Andrea Madami; Antonio Triolo
Journal:  J Mass Spectrom       Date:  2002-12       Impact factor: 1.982

4.  Design of potent competitive inhibitors of angiotensin-converting enzyme. Carboxyalkanoyl and mercaptoalkanoyl amino acids.

Authors:  D W Cushman; H S Cheung; E F Sabo; M A Ondetti
Journal:  Biochemistry       Date:  1977-12-13       Impact factor: 3.162

5.  The disposition of [14C]-labelled benazepril HCl in normal adult volunteers after single and repeated oral dose.

Authors:  F Waldmeier; G Kaiser; R Ackermann; J W Faigle; J Wagner; A Barner; K C Lasseter
Journal:  Xenobiotica       Date:  1991-02       Impact factor: 1.908

6.  Determination of benazepril, a new angiotensin-converting enzyme inhibitor, and its active metabolite, benazeprilat, in plasma and urine by capillary gas chromatography-mass-selective detection.

Authors:  A Sioufi; F Pommier; G Kaiser; J P Dubois
Journal:  J Chromatogr       Date:  1988-12-29

7.  Conformationally restricted inhibitors of angiotensin converting enzyme: synthesis and computations.

Authors:  E D Thorsett; E E Harris; S D Aster; E R Peterson; J P Snyder; J P Springer; J Hirshfield; E W Tristram; A A Patchett; E H Ulm
Journal:  J Med Chem       Date:  1986-02       Impact factor: 7.446

8.  Design of specific inhibitors of angiotensin-converting enzyme: new class of orally active antihypertensive agents.

Authors:  M A Ondetti; B Rubin; D W Cushman
Journal:  Science       Date:  1977-04-22       Impact factor: 47.728

9.  Trace analysis of quinapril and its active metabolite, quinaprilat, in human plasma and urine by gas chromatography-negative-ion chemical ionization mass spectrometry.

Authors:  N Goto; T Kamata; K Ikegami
Journal:  J Chromatogr       Date:  1992-07-24

10.  Liquid chromatography-mass spectrometry method for determination of ramipril and its active metabolite ramiprilat in human plasma.

Authors:  Zhimeng Zhu; Andre Vachareau; Len Neirinck
Journal:  J Chromatogr B Analyt Technol Biomed Life Sci       Date:  2002-11-05       Impact factor: 3.205

View more
  1 in total

1.  Characterization of impurities in the bulk drug lisinopril by liquid chromatography/ion trap spectrometry.

Authors:  Pei-xi Zhu; Dan-hua Wang; Cui-rong Sun; Zhi-quan Shen
Journal:  J Zhejiang Univ Sci B       Date:  2008-05       Impact factor: 3.066

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.